Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genscript Biotech Corp.
Headquarters: Piscataway, NJ, United States of America
Website: http://www.genscript.com
Year Founded: 2002
Status: Public
Industry Sector: HealthTechnology
CEO: Weihui Shao
Number Of Employees: 5,568
Enterprise Value: $2,294,168,811
PE Ratio: 1.17
Exchange/Ticker 1: HKEX:1548
Exchange/Ticker 2: N/A
Latest Market Cap: $3,486,197,762
BioCentury | Jul 18, 2024
Politics, Policy & Law
A takeout could remove CAR T play Legend from Biosecure’s glare
The J&J partner, under scrutiny by House select committee, is said to be attracting M&A interest
BioCentury | Jun 4, 2024
Data Byte
House select committee’s expanded scope weighs on GenScript, Legend
Therapeutic developers now on China committee’s radar, not just CROs
BioCentury | Jun 4, 2024
Deals
Biotech M&A, Biosecure expands & ASCO update: a BioCentury podcast
An M&A quartet. House China committee’s new focus. Colorectal cancer immunotherapies.
BioCentury | May 31, 2024
Politics, Policy & Law
In targeting Legend, House select committee on China expands focus
Letter requesting FBI, intel briefings suggests aperture is widening from CROs and security to therapeutic developers and commercial competitiveness
BioCentury | Sep 1, 2023
Finance
Tier-jumpers: Building the road to sustainable biotechs. Back to School 2023
How companies can build value and climb market cap tiers to reach the top
BioCentury | May 26, 2023
Data Byte
The 20 biggest venture raises year-to-date: genetic medicines dominate
Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines
BioCentury | Jan 20, 2023
Market Access
Jan. 19 Quick Takes: Average price cuts of 60% for new listings on China’s NRDL
Plus: Shoreline buying Editas NK assets and updates from Intercept, Roche, Seagen and more
BioCentury | Oct 7, 2022
Finance
3Q22 Wrap: always darkest before the dawn?
Biotech valuations continued to fall across all market cap tiers in 3Q22
BioCentury | Aug 5, 2022
Management Tracks
Frank Zhang returns to Legend
Plus Protano named CFO at Alltrna, and updates from Laronde, Xentria and more
BioCentury | May 10, 2022
Product Development
May 9 Quick Takes: Madrigal adds co-primary endpoint to NASH study
Plus first EU-listed life sciences SPAC launches and updates from Janssen, Myovant and more
Items per page:
1 - 10 of 65